Long- and Short-Term Cost-Effectiveness of Once-Weekly Semaglutide versus Dulaglutide for the Treatment of Type 2 Diabetes in China: A Hypothetical Modeling Exercise

被引：0
|
作者：
Ying Hu [1 ]
Huimin Zou [2 ]
Yang Shen [3 ]
Qi Ni [4 ]
Yijun Li [1 ]
Hao Zhang [1 ]
Xianwen Chen [5 ]
Carolina Oi Lam Ung [2 ]
Hao Hu [2 ]
Yiming Mu [6 ]
机构：
[1] PLA General Hospital,Department of Endocrinology, First Medical Center of Chinese
[2] University of Macau,State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences
[3] Peking University,School of Public Health
[4] Peking University,China Center for Health Development Studies
[5] Novo Nordisk (China) Pharmaceuticals Co.,Centre for Pharmaceutical Regulatory Sciences
[6] Ltd.,Department of Public Health and Medicinal Administration, Faculty of Health Sciences
[7] University of Macau,undefined
[8] University of Macau,undefined
来源：
Diabetes Therapy | 2025年 / 16卷 / 5期
关键词：
Type 2 diabetes; Semaglutide; Dulaglutide; Cost-effectiveness analysis; China;
D O I：
10.1007/s13300-025-01716-9
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：915 / 929
页数：14
相关论文
共 50 条
  • [1] Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada
    Pierre Johansen
    Jonas Håkan-Bloch
    Aiden R. Liu
    Peter G. Bech
    Sofie Persson
    Lawrence A. Leiter
    PharmacoEconomics - Open, 2019, 3 : 537 - 550
  • [2] Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada
    Johansen, Pierre
    Hakan-Bloch, Jonas
    Liu, Aiden R.
    Bech, Peter G.
    Persson, Sofie
    Leiter, Lawrence A.
    PHARMACOECONOMICS-OPEN, 2019, 3 (04) : 537 - 550
  • [3] The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type 2 Diabetes: A Cost of Control Analysis in Spain
    Josep Vidal
    Samuel J. P. Malkin
    Barnaby Hunt
    Virginia Martín
    Nino Hallén
    Francisco Javier Ortega
    Diabetes Therapy, 2020, 11 : 509 - 521
  • [4] The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type 2 Diabetes: A Cost of Control Analysis in Spain
    Vidal, Josep
    Malkin, Samuel J. P.
    Hunt, Barnaby
    Martin, Virginia
    Hallen, Nino
    Javier Ortega, Francisco
    DIABETES THERAPY, 2020, 11 (02) : 509 - 521
  • [5] Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK
    Viljoen, Adie
    Hoxer, Christina S.
    Johansen, Pierre
    Malkin, Samuel
    Hunt, Barnaby
    Bain, Stephen C.
    DIABETES OBESITY & METABOLISM, 2019, 21 (03): : 611 - 621
  • [6] The long-term cost-effectiveness of once-weekly semaglutide versus sitagliptin for the treatment of type 2 diabetes in China
    Shuyan Gu
    Jinghong Gu
    Xiaoyong Wang
    Xiaoling Wang
    Lu Li
    Hai Gu
    Biao Xu
    Health Economics Review, 14
  • [7] The long-term cost-effectiveness of once-weekly semaglutide versus sitagliptin for the treatment of type 2 diabetes in China
    Gu, Shuyan
    Gu, Jinghong
    Wang, Xiaoyong
    Wang, Xiaoling
    Li, Lu
    Gu, Hai
    Xu, Biao
    HEALTH ECONOMICS REVIEW, 2024, 14 (01)
  • [8] Lower Drug Cost of Successfully Treating Patients with Type 2 Diabetes to Targets with Once-Weekly Semaglutide versus Once-weekly Dulaglutide in Japan: A Short-Term Cost-Effectiveness Analysis
    Ataru Igarashi
    Barnaby Hunt
    Lars Wilkinson
    Jakob Langer
    Richard F. Pollock
    Advances in Therapy, 2020, 37 : 4446 - 4457
  • [9] The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia
    Malkin, Samuel J. P.
    Russel-Szymczyk, Monika
    Psota, Marek
    Hlavinkova, Lucia
    Hunt, Barnaby
    ADVANCES IN THERAPY, 2019, 36 (08) : 2034 - 2051
  • [10] Lower Drug Cost of Successfully Treating Patients with Type 2 Diabetes to Targets with Once-Weekly Semaglutide versus Once-weekly Dulaglutide in Japan: A Short-Term Cost-Effectiveness Analysis
    Igarashi, Ataru
    Hunt, Barnaby
    Wilkinson, Lars
    Langer, Jakob
    Pollock, Richard F.
    ADVANCES IN THERAPY, 2020, 37 (10) : 4446 - 4457
12345